Zomepirac

Summary

Zomepirac (CHEMBL19490) is an approved small-molecule non-steroidal anti-inflammatory drug (ATC M01AB04); indicated across 1 condition including rheumatic disorder.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: M01AB04
• Indications: 1 condition
• Chemistry: 291.73 Da · C15H14ClNO3

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL19490
Name	Zomepirac
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	5733
ChEBI	CHEBI:35859
ATC	M01AB04
Molecular formula	C15H14ClNO3
Molecular weight	291.73
InChIKey	ZXVNMYWKKDOREA-UHFFFAOYSA-N

SMILES: CC1=C(N(C(=C1)CC(=O)O)C)C(=O)C2=CC=C(C=C2)Cl

IUPAC name: 2-[5-(4-chlorobenzoyl)-1,4-dimethylpyrrol-2-yl]acetic acid

Pharmacological roles (ChEBI): non-steroidal anti-inflammatory drug, cardiovascular drug.

Also known as: Zomepirac, Zomepiraco, SID26752779, zomepirac, ZOMEPIRAC

Parent form; salt/anhydrous children: CHEMBL3989403, CHEMBL4764346

Patent coverage: 4,794 distinct patent families (19,546 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 5 (assay-derived). Sample: Fructose-bisphosphate aldolase, Cyclooxygenase, Prostaglandin G/H synthase 2, Prostaglandin G/H synthase 1, Bile salt export pump.

Bioactivity

ChEMBL activities: 1 potent at pChembl ≥ 5 of 5 total. Top 100 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
PTGS2	5.92	AC50	1200	nM	CHEMBL_ACT_25166499

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 approved indication. FDA phase 4, plus an anticancer drug’s labelled cancer uses (which ChEMBL often logs at phase 3).

Indication	Phase	MONDO	EFO
rheumatic disorder	4	MONDO:0005554	EFO:0005755

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline or drug-level clinical/variant annotations in PharmGKB for this molecule.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).